CLINICAL TRIALS PROFILE FOR TRORILUZOLE

Clinical Trials for troriluzole

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02960893 ↗	Trial in Adult Subjects With Spinocerebellar Ataxia	Active, not recruiting	Cognitive Research Corporation	Phase 2/Phase 3	The primary purpose of this study is to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
NCT02960893 ↗	Trial in Adult Subjects With Spinocerebellar Ataxia	Active, not recruiting	Cytel Inc.	Phase 2/Phase 3	The primary purpose of this study is to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
NCT02960893 ↗	Trial in Adult Subjects With Spinocerebellar Ataxia	Active, not recruiting	Biohaven Pharmaceutical Holding Company Ltd.	Phase 2/Phase 3	The primary purpose of this study is to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
NCT02960893 ↗	Trial in Adult Subjects With Spinocerebellar Ataxia	Active, not recruiting	Biohaven Pharmaceuticals, Inc.	Phase 2/Phase 3	The primary purpose of this study is to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
NCT03605667 ↗	Study of BHV-4157 in Alzheimer's Disease	Active, not recruiting	Alzheimer's Disease Cooperative Study (ADCS)	Phase 2/Phase 3	Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, taken orally once daily. Duration of treatment is 48 weeks. There is also a screening period of up to 42 days; and a 4-week post-treatment observation period.
NCT03605667 ↗	Study of BHV-4157 in Alzheimer's Disease	Active, not recruiting	Biohaven Pharmaceuticals, Inc.	Phase 2/Phase 3	Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, taken orally once daily. Duration of treatment is 48 weeks. There is also a screening period of up to 42 days; and a 4-week post-treatment observation period.

Clinical Trial Conditions for troriluzole

Condition Name

Condition Name
Intervention	Trials
Spinocerebellar Ataxia Type 1	2
Spinocerebellar Ataxia Type 10	2
Spinocerebellar Ataxia Type 2	2
Obsessive-Compulsive Disorder	2

Condition MeSH

Condition MeSH
Intervention	Trials
Disease	4
Obsessive-Compulsive Disorder	3
Compulsive Personality Disorder	3
Spinocerebellar Degenerations	2

Clinical Trial Locations for troriluzole

Trials by Country

Trials by Country
Location	Trials
United States	143
Canada	4
United Kingdom	3
China	2
Netherlands	2

Trials by US State

Trials by US State
Location	Trials
Texas	7
New York	7
Massachusetts	7
Florida	7
California	7

Clinical Trial Progress for troriluzole

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	5
Phase 2/Phase 3	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	3
Active, not recruiting	3
Completed	1

Clinical Trial Sponsors for troriluzole

Sponsor Name

Sponsor Name
Sponsor	Trials
Biohaven Pharmaceuticals, Inc.	8
Cytel Inc.	1
Biohaven Pharmaceutical Holding Company Ltd.	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	10
Other	3